Optimization of the Protocol for the Isolation and Refolding of the Extracellular Domain of HER2 Expressed in Escherichia coli

Cover Page

Cite item

Full Text

Abstract

Receptor 2 of the human epidermal growth factor (HER2/neu, c-erbB2) is a 185 kDa proto-oncogene protein characterized by an overexpression in some oncological diseases, including 30% of mammary glands cancers, as well as tumors in the ovary, stomach and other organs of the human body. Since HER2- tumor status testing is the essential part of a successful cancer treatment, the expression and purification of substantial amounts of the extracellular domain (ECD) of HER2 is an important task. The production of ECD HER2 in Escherichia coli has several advantages over the use of eukaryotic expression systems, but the bulk of the recombinant product in bacteria accumulates as insoluble protein inclusion bodies. In this study, we obtained ECD HER2 in Escherichia coli as insoluble inclusion bodies and elaborated a simple, efficient, and fast protocol for the solubilization, refolding, and isolation of the protein in soluble form.

About the authors

V. V. Dolgikh

Department of Microbiology, Virology and Immunology, First Pavlov State Medical University of Saint Petersburg

Author for correspondence.
Email: vtetzv@yahoo.com
Россия

I. V. Senderskiy

Department of Microbiology, Virology and Immunology, First Pavlov State Medical University of Saint Petersburg

Email: vtetzv@yahoo.com
Россия

G. V. Tetz

Department of Microbiology, Virology and Immunology, First Pavlov State Medical University of Saint Petersburg

Email: vtetzv@yahoo.com
Россия

V. V. Tetz

Department of Microbiology, Virology and Immunology, First Pavlov State Medical University of Saint Petersburg

Email: vtetzv@yahoo.com
Россия

References

  1. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., Francke U. // Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. // Science. 1985, V.230, P.1132-1139
  2. Marmor M.D., Skaria K.B., Yarden Y. // Signal transduction and oncogenesis by ErbB/HER receptors. // Int. J. Radiat. Oncol. Biol. Phys. 2004, V.58, P.903-913
  3. Tan M., Yu D. // Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. // Adv. Exp. Med. Biol. 2007, V.608, P.119-29
  4. Santin A.D., Bellone S., Roman J.J., McKenney J.K., Pecorelli S. // Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER 2/neu. // Int. J. Gynaecol. Obstet. 2008, V.102, №2, P.128-31
  5. Menard S., Balsari A., Casalini P., Tagliabue E., Campiglio M., Bufalino R., Cascinelli N. S. // HER -2-positive breast carcinomas as a particular subset with peculiar clinical behavior // Clin. Cancer Res. 2002, V.8, P.520-525
  6. Sandri M.T., Johansson H., Colleoni M., Zorzino L., Passerini R., Orlando L., Viale G. // Serum levels of HER 2 EC D can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. // Anticancer Res. 2004, V.24, P.1261-1266
  7. Disis M.L., SchiVman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., dela Rosa C., Cheever M.A. // Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. // J. Clin. Oncol. 1996, V.22, №10, P.1916-1925
  8. Pichon M.F., Hacene K., Guepratte S., Neumann R. // Serum HER -2 extracellular domain (EC D) before the first metastasis in 128 breast cancer // Clin. Lab. 2004, V.50, №3-4, P.163-170
  9. Leary A.F., Hanna W.M., van de Vijver M.J., Penault-Llorca F., Rüschoff J., Osamura R.Y., Bilous M., Dowsett M. // Serum HER -2 extracellular domain (EC D) before the first metastasis in 128 breast cancer patients. // Clin. Lab. 2009, V.27, №10, P.1694-1705
  10. Lennon S., Barton C., Banken L., Gianni L., Marty M., Baselga J., Leyland-Jones B. // Utility of serum HER 2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. // J Clin Oncol. 2009, V.27, №10, P.1685-1693
  11. Belimezi M.M., Papanastassiou D., Merkouri E., Baxevanis C.N., Mamalaki A. // Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. // Cancer Immunol. Immunother. 2006, V.55, №9, P.1091-1099
  12. Liu X., He Z., Zhou M., Yang F., Lv H., Yu Y., Chen Z. // Purification and characterization of recombinant extracellular domain of human HER 2 from Escherichia coli. // Protein Expr. Purif. 2007, V.53, №2, P.247-254
  13. Dimitriadis A., Gontinou C., Baxevanis C.N., Mamalaki A. // The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity. // BMC Cancer. 2009, V.9, P.386
  14. Waugh D.S. // Making the most of affinity tags. // Trends Biotechnol. 2005, V.23, №6, P.316-320
  15. Nallamsetty S., Waugh D. // Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. // Protein Expr. Purif. 2006, V.45, №1, P.175-182
  16. Nallamsetty S., Waugh D.S. // A generic protocol for the expression and purification of recombinant proteins in Escherichia coli using a combinatorial His6-maltose binding protein fusion tag. // Nature Protocols 2007, V.2, №2, P.383-391
  17. Dolgikh V.V., Senderskiy I.V., Tetz G.V., Tetz V.V. // Extracellular domain of HER 2 heterologous expression in bacteria. Accepted for publication by Uchenye zapiski Sankt-Peterburguskogo Gosudarstvennogo Meditsinskogo Universiteta im. acad. I.P. Pavlova (Proceedings of St. Petersburg State Pavlov Medical University) in September 2013 (in Russian). 2013
  18. Vogelstein B., Gillespie D. // Proc. Natl. Acad. Sci. USA. 1979, V.76, №2, P.615-619
  19. Miroux B., Walker J.E. // J. Mol. Biol. 1996, V.260, P.289-298
  20. Laemmli U.K. // Nature 1970, V.227, P.680-685
  21. Cleland W.W. // Biochemistry. 1964, V.3, P.480-482

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Dolgikh V.V., Senderskiy I.V., Tetz G.V., Tetz V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.